Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial
Nerea Ancizar, Xavier González, Antonio Llombart‐Cussac, María Gión et al.
Citations
8 citations
Journal
EClinicalMedicine
Topics
Advanced Breast Cancer Therapies
Field-Weighted Citation Impact (FWCI)
12.15
article
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial
Nerea Ancizar, Xavier González, Antonio Llombart‐Cussac, María Gión, Isabel Blancas, Sabela Recalde, Manuel Ruíz‐Borrego, Javier Cortés, Elena López-Miranda, Alejandro Martínez‐Bueno, Miguel Sampayo-Cordero, José Antonio López‐Guerrero, Serafin M. Morales, Cristina Reboredo Rendo, Patricia Cortez, J. M. Perez-Garcia, Salvador Blanch, Eileen Shimizu, Zuzanna Piwowarska
article en
8 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 85
Institutions
Universidad de Granada (ES), Universidad Cardenal Herrera CEU (ES), Hospital Universitari Arnau de Vilanova (ES), Hospital Universitario de Torrejón (ES), Instituto Oncológico Dr. Rosell (ES), MedSIR (Spain) (ES), Fundación Instituto Valenciano de Oncología (ES), Institut Català d'Oncologia (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital Arnau de Vilanova (ES), Hospital General de Catalunya (ES), Hospital de Sant Joan Despí Moisès Broggi (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Ruber Internacional (ES), Hospital Universitario Virgen del Rocío (ES), International Breast Cancer Study Group (CH), Hospital Universitario Ramón y Cajal (ES), Universidad Europea de Madrid (ES)
Funders
Gilead Sciences, American Society of Clinical Oncology